Background: Controversy remains on whether the dual use of clopidogrel and proton-pump inhibitors (PPIs) affects clinical efficacy of clopidogrel.
C
lopidogrel is a platelet inhibitor that reduces the risk for new ischemic cardiovascular events, in combination with aspirin, in patients treated either medically or with percutaneous coronary intervention (PCI) after myocardial infarction (1) (2) (3) . Proton-pump inhibitors (PPIs) are often given in combination with clopidogrel and aspirin to reduce the risk for upper gastrointestinal bleeding. Clopidogrel is a prodrug that is metabolized to an active metabolite primarily by the hepatic P-450 enzyme 2C19 (4) . Because PPIs are metabolized by the same hepatic isoenzyme (5), concern has been raised that PPIs might inhibit the conversion of clopidogrel to its active metabolite and thereby diminish its clinical benefit.
Recent studies show that PPIs reduce the ex vivo inhibition of platelet aggregation achieved during treatment with clopidogrel (6 -8) . Clinical studies involving selected populations (9 -13) show conflicting results regarding risk for adverse cardiovascular events associated with the dual use of clopidogrel and PPIs. The U.S. Food and Drug Administration (14, 15) and the European Medicines Agency (16) have recently discouraged the combined use of these agents unless strongly indicated, while emphasizing the need for further studies. We sought to examine the risk for adverse cardiovascular outcomes related to concomitant use of PPIs and clopidogrel compared with that of PPIs alone in a large, unselected cohort of patients hospitalized with first-time myocardial infarction. nationwide cohort study linked Danish national registry data relevant to hospitalizations, pharmacy prescription claims, and deaths for 4.65 million people.
For all hospital admissions in Denmark, the Danish National Patient Registry registers a primary diagnosis and, if appropriate, 1 or more secondary diagnoses, as defined by the International Classification of Diseases. The Danish Registry of Medicinal Product Statistics (a national prescription registry) records every prescription dispensed from pharmacies in Denmark, and each drug is classified according to the International Anatomical Therapeutical Chemical system. Information on vital status and causes of death were obtained, respectively, from the Danish Civil Registry and the National Causes of Death Registry.
The Danish Data Protection Agency approved the study, and the data made available to us were such that individuals could not be identified. Retrospective registry studies do not require ethical approval in Denmark. The authors had full access to the data and take full responsibility for its integrity.
Patient Population
From the National Patient Registry, we identified all consecutive patients older than 30 years who were hospitalized with acute myocardial infarction between 2000 and 2006 in Denmark. To ensure the homogeneity of our population, patients with previous myocardial infarction and patients with partially missing data were excluded. We depended on patients filling prescriptions to identify users. Our primary analysis included patients who survived at least 30 days because we reasoned that a 30-day period would facilitate correct classification of drug use; most patients who filled their prescriptions did so within 30 days (Appendix Figure 1 , available at www.annals.org). We also examined the sensitivity of the results to the 30-day cutoff by examining alternative cohorts that included patients who survived 7, 14, and 21 days after myocardial infarction. Patients who emigrated were censored at the time of emigration.
Drug Use
Using the national prescription registry, we identified all prescriptions of drugs claimed up to 90 days after discharge (Table 1) , as well as all prescriptions for PPIs and H 2 -antagonists claimed within 1 year after discharge. Information on medication exposure for each day of follow-up was also obtained, including dispensing date, type, quantity, dose of drug, and days of drug supply. No data on patient-reported adherence were available. We defined current use as the period from the prescription filling date to the calculated end of the period drug supply. Of note, the national prescription registry has demonstrated accuracy (17) , and the use of clopidogrel is reasonably stable over time in this cohort, with a 1-year persistency of 89% after 2004 (18) .
Outcomes
The primary outcome was a composite of rehospitalization for myocardial infarction or stroke or cardiovascular death. Secondary outcomes included all-cause death, cardiovascular death, and rehospitalization for myocardial infarction, stroke, or gastrointestinal bleeding. Follow-up was up to 1 year after discharge. The diagnoses of acute myocardial infarction and stroke have been validated in the Danish National Patient Registry (19, 20) .
Comorbidity
Comorbid conditions were established on the basis of diagnoses noted at the time of discharge from the index myocardial infarction, as specified in the Ontario acute myocardial infarction mortality prediction rule (21) . The comorbidity index was further enhanced by adding diagnoses from the year before the event, as was done by Rasmussen and colleagues (22).
Concomitant use of loop diuretics or diabetes medication was a proxy for heart failure or diabetes, respectively, to define high-risk subgroups of patients, as was done by Gislason and colleagues (23) .
Statistical Analysis
We used 2 statistical methods to estimate the risk associated with PPI treatment with or without concomitant treatment with clopidogrel.
First, we used Cox proportional hazards models to derive hazard ratios (HRs) and 95% CIs. These models were adjusted for the variables shown in Table 1 , including age, sex, PCI, income, concomitant medical treatment, and comorbid conditions. Exposure to PPIs was included as a time-dependent covariate.
Context
Observational studies show mixed signals about risk for cardiovascular events with the dual use of proton-pump inhibitors (PPIs) and clopidogrel compared with clopidogrel alone.
Contribution
This observational study, based on administrative data from all hospitals in Denmark, found that patients who received clopidogrel and PPIs at discharge after a first-time myocardial infarction had similar risks for cardiovascular death, myocardial infarction, or stroke as did those of patients who received PPIs alone.
Caution
Possible confounding and no information on adherence or over-the-counter drug use limit interpretation.
Implication
Concurrent PPI and clopidogrel use after myocardial infarction may not be associated with additional risk over that observed with PPIs alone.
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Increased Cardiovascular Risk With Proton-Pump Inhibitors Second, we performed a propensity score-matched analysis, in which we quantified a propensity score for the likelihood of receiving a PPI in the first year after discharge by using multivariate logistic regression analysis, conditional on the baseline covariates specified in Table 1 . Using the Greedy matching macro (http://mayoresearch.mayo.edu /mayo/research/biostat/upload/gmatch.sas; accessed on 27 July 2010), we matched each case patient to a control participant on the basis of propensity score. Use of PPIs was included as a time-dependent covariate, and propensity scorematched Kaplan-Meier estimates were generated to show event rates and time-to-event curves.
To assess the robustness of our results, we performed a series of additional analyses, including an analysis that evaluated how large the effect of an unmeasured confounder would need to be to explain the results, subgroup analyses of different types of PPIs, and a dose-dependent analysis (24) . We also assessed the variation of both PPI use and outcome between hospitals and performed a stratified analysis according to PCI and aspirin use. All statistical calculations were performed with SAS, version 9.2 (SAS Institute, Cary, North Carolina).
Role of the Funding Source
Our study was funded by the Danish Medical Research Council and the Danish Heart Foundation. The study sponsors had no influence on the study design, data collection, analysis, data interpretation, or decision to submit the manuscript for publication.
RESULTS
Patients
A total of 71 987 patients were admitted with myocardial infarction from 2000 to 2006 (Figure 1 ). Of these, we excluded 1889 patients with previous myocardial infarction, 13 324 patients who died during hospitalization or within 30 days of discharge, and 368 patients with partially missing data. Of the 56 406 patients included in the study, 24 704 (43.8%) claimed a prescription for clopidogrel within 30 days of discharge (Appendix Figure 1 ). Of these, 6753 patients (27.3%) claimed at least 1 prescription for PPIs within 1 year of discharge. The use of PPIs was equal in the 2 cohorts and independent of clopidogrel use (Appendix Table 1 , available at www.annals.org). Table 1 shows baseline characteristics of the study sample at the time of inclusion. Patients who received clopidogrel were younger, were more often male, received less concomitant medical treatment, had fewer comorbid conditions, and more often had PCI than patients who did not ACE ϭ angiotensin-converting enzyme; PCI ϭ percutaneous coronary intervention; PPI ϭ proton-pump inhibitor. * All values are numbers (percentages) unless otherwise indicated.
receive clopidogrel. Patients who received PPIs were older, were more often female, received more concomitant medical treatment, and had more comorbid conditions than those who did not receive PPIs.
Outcome
In the first year after inclusion, 9137 (16.2%) cardiovascular deaths and rehospitalizations for myocardial infarction or strokes were registered (Appendix Table 2 , available at www.annals.org). Clopidogrel was associated with lower event rates, and PPIs were associated with higher event rates. The event rates were highest among patients who received a PPI but not clopidogrel (26.3%).
Cox Proportional Hazards Regression Analysis
The time-dependent Cox proportional hazards regression analysis ( Table 2) , based on patients who filled prescriptions for clopidogrel within 30 days of discharge, demonstrated an increased risk for the primary end point (cardiovascular death or rehospitalization for myocardial infarction or stroke) among patients who received both clopidogrel and a PPI (HR, 1.29 [95% CI, 1.17 to 1.42]; P Ͻ 0.001) compared with those who did not receive a PPI. Among patients who did not receive clopidogrel, PPI therapy was associated with a similar increase in risk (HR, 1.29 [CI, 1.21 to 1.37]; P Ͻ 0.001). Results were consistent for the risk for all secondary outcomes ( Table 2) . The hazard rate ratio of the effect of the interaction between PPI and clopidogrel for the primary outcome analysis was 0.98 (CI, 0.88 to 1.10; P ϭ 0.72).
Time-Dependent, Propensity Score-Matched Cox Proportional Hazards Regression Analysis
Using the propensity score generated from logistic regression models conditional on baseline covariates, we matched 6556 patients who received both clopidogrel and a PPI with the same number of patients who received clopidogrel but not a PPI. We also matched 8437 patients who did not receive clopidogrel but did receive a PPI with the same number of patients who received neither clopidogrel nor a PPI. Use of PPIs was included as a timedependent covariate. The c-statistics were 0.65 and 0.65 for the clopidogrel and nonclopidogrel groups, respectively, which indicates an acceptable discriminative power for the models. Table 1 shows the baseline characteristics of the propensity score-matched populations and P values for the between-group differences (Appendix Tables 3 and  4 and Appendix Figure 2 , available at www.annals.org, provide further details). For use of a PPI in combination with clopidogrel, with no PPI therapy as the reference, the HR for cardiovascular death or rehospitalization for myocardial infarction or stroke was 1.35 (CI, 1.22 to 1.50; P Ͻ 0.001), whereas the HR for use of a PPI without clopidogrel was 1.43 (CI, 1.34 to 1.53; P Ͻ 0.001). Analysis of the risk for the secondary outcomes generated similar results ( Table 2 ). The propensity score-matched KaplanMeier analysis (Figure 2 ) depicts the elevated risk for cardiovascular death or rehospitalization for myocardial infarction or stroke for patients who received PPIs with or without clopidogrel.
Subgroup Analyses of Different Types of PPIs
Of the 15 642 patients who claimed at least 1 prescription for PPIs, 4698 (30.0%) claimed prescriptions for pantoprazole, 2798 (17.9%) for lansoprazole, 2717 (17.4%) for omeprazole, 5316 (34.0%) for esomeprazole, and 113 (0.01%) for rabeprazole. Results from the timedependent, Cox proportional hazards regression analysis and the Kaplan-Meier cumulative hazard estimates demonstrated no difference in risk associated with the type of PPI independent of clopidogrel treatment (Appendix Figures 3 and 4 , available at www.annals.org). We did not include rabeprazole data in this analysis because the cohort was too small to generate reliable results.
Additional Analyses
In the propensity score matching based on baseline covariates that predicted treatment with a PPI, the risk reduction for gastrointestinal bleeding in patients who received clopidogrel and a PPI was 0.82 (CI, 0.63 to 1.07; P ϭ 0.140) compared with patients who did not receive a PPI. Therapy with a PPI had no effect in the group that did not receive clopidogrel (risk reduction, 0.99 [CI, 0.80 to 1.22]; P ϭ 0.89).
We estimated that an unmeasured confounder would have to elevate risk by 2.5 to 3 to fully explain the in- MI ϭ myocardial infarction; PPI ϭ proton-pump inhibitor.
Article Increased Cardiovascular Risk With Proton-Pump Inhibitors creased risk for cardiovascular events observed with either PPI or clopidogrel and PPI (Appendix Figure 5 , available at www.annals.org). To ensure the validity of using day 30 after discharge as the inclusion day, we examined differences in baseline characteristics at discharge and at day 30. We found that most patients (83.5%) who died in the first 30 days were from the cohort that had not filled prescriptions for clopidogrel or a PPI (Appendix Table 5 , available at www.annals.org). Examinations of the study cohort at various assembly time points, including 7 and 21 days after myocardial infarction, revealed no differences in the hazard rate ratios of the effect of the interaction between PPIs and clopidogrel ( Table 3 ). An analysis subdivided by patients seen before and after 2004 provided no evidence of any differences in the effect of PPIs on outcome (P ϭ 0.14). Interaction analyses between relevant subgroups of patients, PPI therapy, and outcome showed interactions (P ϭ 0.035) for concomitant treatment with a PPI and clopidogrel and PCI, with a statistically significant higher risk for cardiovascular death or rehospitalization for myocardial infarction or stroke in a stratified analysis (HR, Figure 6 , available at www.annals .org). Stratifying patients by concomitant aspirin treatment showed no effect. Additional sensitivity analyses demonstrated no evidence of any clustering between hospitals and no evidence of any difference between high and low PPI doses (Appendix Figure 7 and Appendix Table 6 , available at www.annals.org)
DISCUSSION
We found no evidence that concomitant PPI therapy increases risk for adverse cardiovascular events in patients who receive clopidogrel.
We conducted a MEDLINE search to find major studies between 2003 and 2010 that investigated possible interactions between clopidogrel and PPIs. Gilard and colleagues (6, 7) first drew attention to a possible interaction in a double-blind study that showed a reduced ex vivo antiplatelet effect of clopidogrel when combined with a PPI. Other studies (8, 14, 20, 21) have confirmed this finding.
An intense debate is now occurring about whether the diminished ex vivo antiplatelet effect is of clinically significant importance. Several large observational studies (9 -11, 25) found concomitant use of clopidogrel and a PPI to be associated with increased risk for death or rehospitalization for myocardial infarction. However, these studies were not based on populations that represent the average patient PPI ϭ proton-pump inhibitor. (11) also found baseline PPI use to be associated with increased cardiovascular events, regardless of whether clopidogrel was used. These studies were based on selected patients eligible for randomized trials, who were usually younger and less likely to have significant comorbid conditions than many patients who are prescribed both clopidogrel and a PPI. The prospective, randomized COGENT (Clopidogrel and the Optimization of Gastrointestinal Events) study (26) , which was stopped before inclusion of patients was complete, evaluated the cardiovascular safety of concomitant treatment with omeprazole and clopidogrel and found no evidence of increased cardiovascular risk. Similar results were recently reported by Ray and colleagues (13) . Of note, preliminary results from the COGENT study demonstrated an increased risk for gastrointestinal bleeding in patients who received dual antiplatelet treatment without PPI therapy. This increased bleeding risk was confirmed by Yasuda and colleagues (27) , which emphasizes the importance of establishing the cardiovascular safety of concomitant PPI treatment. Ray and colleagues' study (13) also illustrated the efficacy of PPI therapy in combination with dual antiplatelet treatment by showing a remarkable reduction in risk for gastrointestinal bleeding in patients who received combination therapy. Our study furthers the research in this area by investigating the risk for cardiovascular events in a nationwide, unselected population that represents the average patient who has had a myocardial infarction. We demonstrated that PPI therapy did not modify the effect of clopidogrel on cardiovascular outcomes and that PPI use was associated with increased cardiovascular risk independent of concomitant use of clopidogrel.
We suspect that the increased cardiovascular risk in all patients who received a PPI can be explained by differences in baseline comorbid conditions that were unmeasured or measured imperfectly. Such unmeasured confounders would have to elevate the risk 2.5-to 3-fold to explain the observed increased risk for cardiovascular events. This is a large but potentially plausible amount of risk elevation for a confounder or a mix of confounders, particularly because these registry data lacked detailed information on risk factors, such as smoking, lipid levels, body mass index, and left ventricle ejection fraction.
We also demonstrated a reduction in risk for gastrointestinal bleeding related to PPI therapy for patients who received clopidogrel, although it did not reach statistical significance. In Denmark, PPIs are prescribed mainly for patients with a clear indication, such as peptic ulcer. Thus, we expected the cohort of patients treated with PPIs to be heavily confounded by the indication for PPIs and to have a higher bleeding risk than patients in countries where guidelines recommend routine use of PPIs in combination with dual antiplatelet therapy. This may explain why our study did not find a statistically significant protective effect of PPIs on risk for gastrointestinal bleeding.
Previous studies (9, 10) have reported that the risk for adverse cardiovascular outcomes was particularly increased by concomitant treatment with omeprazole and clopidogrel, on the basis of proposed differences in drug-specific metabolism and diminished antiplatelet effects ex vivo (6, 7, 23) . Our data set provided no evidence of differences in risk between the subtypes of PPIs, with or without clopidogrel. Sensitivity analyses also provided no evidence of differences in risk related to heart failure, diabetes, age, hospitals, or PPI dosages. However, we did find a statistically significant interaction between PCI and PPIs in the group that received clopidogrel.
Several considerations and limitations may affect the interpretation of our results. We had no self-reported patient data regarding adherence. We were also dependent on patients filling prescriptions after discharge, and we chose Article Increased Cardiovascular Risk With Proton-Pump Inhibitors day 30 as the inclusion day for primary analyses to avoid a potential immortal time bias. The comparison of baseline characteristics between day 30 and discharge ( Table 1 and  Appendix Table 5 ) illustrates this potential bias, because 83.5% of the patients who died in the first 30 days were in the cohort who did not fill a prescription for either clopidogrel or a PPI. The high 30-day mortality rate in this cohort can be explained by the inclusion of high-risk patients who may not have received clopidogrel or a PPI by the choice of their physicians, whereas other high-risk patients who were actually given prescriptions at discharge could have been too sick to fill their prescriptions or could have been readmitted to the hospital before they filled them. Of note, we examined the cohort at various assembly time points, including 7 and 21 days after myocardial infarction, and found no differences in the hazard rate ratios of the effect of the interaction between PPIs and clopidogrel in relation to assembly time point. Our study's strengths include the large size of our cohort based on a nationwide, unselected population that represents average patients in a contemporary clinical setting who have had a myocardial infarction. The Danish National Patient Registry includes all hospital admissions in Denmark and is therefore not affected by selection bias stemming from selective inclusion of specific hospitals, health insurance systems, or age groups. The concordance between drug dispensing and drug consumption is probably high, because reimbursement of drug expenses is only partial, and most drugs, including PPIs, were not available over the counter in Denmark during the study period (exceptions include aspirin and H 2 -antagonists). Because of the partial reimbursement of drug expenses by Danish authorities, we reasonably assumed that a patient who claimed a prescription from the pharmacy intended to take the drug.
Our study has additional limitations. Clopidogrel resistance has been linked to genotype polymorphisms. Although we have no knowledge of the precise distribution of these polymorphisms in our largely white study population, several studies (28, 29) based in the countries that surround Denmark found variations in relevant genes that matched those reported earlier for white populations. However, generalizing these data to other racial and ethnic groups should be done with caution. Finally, we had no information on the indications for PPI therapy.
In conclusion, PPIs seem to be associated with an increased risk for adverse cardiovascular outcomes regardless of clopidogrel use, but concomitant PPI and clopidogrel use was not associated with any additional increase in risk over that observed for patients who received a PPI alone. We believe that the increased cardiovascular risk associated with PPI use independent of clopidogrel is caused by unmeasured confounders. These results seem to refute concerns about increased risk for ischemic events during concomitant PPI and clopidogrel therapy. ACE ϭ angiotensin-converting enzyme; PCI ϭ percutaneous coronary intervention; PPI ϭ proton-pump inhibitor.
* All values are numbers (percentages) unless otherwise indicated.
